ImmunoGen, Inc.

2019 Q3 Form 10-Q Financial Statement

#000155837019007500 Filed on August 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2018 Q2

Balance Sheet

Concept 2019 Q3 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $204.5M $239.8M $345.1M
YoY Change -32.56% -30.51% 129.61%
Cash & Equivalents $204.5M $239.8M $345.1M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $5.000M $6.600M $9.900M
YoY Change -20.63% -33.33% 106.25%
Inventory $1.900M
Prepaid Expenses
Receivables $3.100M $2.500M $500.0K
Other Receivables $13.10M $10.40M $7.300M
Total Short-Term Assets $225.7M $259.4M $364.6M
YoY Change -30.06% -28.86% 125.9%
LONG-TERM ASSETS
Property, Plant & Equipment $9.118M $10.05M $12.00M
YoY Change -30.92% -16.23% -28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.413M $1.850M $4.400M
YoY Change -12.49% -57.95% 41.94%
Total Long-Term Assets $28.46M $28.29M $16.50M
YoY Change 65.44% 71.46% -17.5%
TOTAL ASSETS
Total Short-Term Assets $225.7M $259.4M $364.6M
Total Long-Term Assets $28.46M $28.29M $16.50M
Total Assets $254.1M $287.7M $381.1M
YoY Change -25.23% -24.52% 110.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.227M $7.809M $12.90M
YoY Change -30.51% -39.47% 148.08%
Accrued Expenses $30.10M $37.00M $26.40M
YoY Change -12.5% 40.15% 35.38%
Deferred Revenue $14.82M $317.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $88.17M $74.62M $63.30M
YoY Change 25.25% 17.88% -6.08%
LONG-TERM LIABILITIES
Long-Term Debt $2.100M $2.100M $2.100M
YoY Change 0.0% 0.0% -97.84%
Other Long-Term Liabilities $970.0K $1.943M $226.5M
YoY Change -99.56% -99.14% 19.21%
Total Long-Term Liabilities $970.0K $1.943M $228.6M
YoY Change -99.56% -99.15% -20.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $88.17M $74.62M $63.30M
Total Long-Term Liabilities $970.0K $1.943M $228.6M
Total Liabilities $340.4M $355.8M $291.9M
YoY Change 16.16% 21.91% -17.68%
SHAREHOLDERS EQUITY
Retained Earnings -$1.300B -$1.300B
YoY Change
Common Stock $1.206B $1.202B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$86.23M -$68.17M $89.19M
YoY Change
Total Liabilities & Shareholders Equity $254.1M $287.7M $381.1M
YoY Change -25.23% -24.52% 110.09%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2018 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
IMGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Entity Central Index Key
EntityCentralIndexKey
0000855654
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
149885000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149400000
CY2018Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MA
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2018Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:PropertyPlantAndEquipmentNet
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-17999
dei Entity Registrant Name
EntityRegistrantName
ImmunoGen, Inc.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-2726691
dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
895-0600
CY2018Q4 us-gaap Assets Current
AssetsCurrent
278781000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10052000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12891000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16389000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1850000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3709000
CY2019Q2 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
715000
CY2019Q2 us-gaap Assets
Assets
287669000
CY2018Q4 us-gaap Assets
Assets
295381000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7809000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11365000
CY2019Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19564000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11796000
CY2019Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14681000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20465000
CY2018Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
837000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4462000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
259378000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
149884816
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239825000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262252000
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1701000
CY2019Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
2474000
CY2018Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
617000
CY2018Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
500000
CY2019Q2 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
10430000
CY2018Q4 imgn Non Cash Royalty Receivable
NonCashRoyaltyReceivable
9249000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6649000
CY2018Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Current
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesCurrent
753000
CY2019Q2 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
29484000
CY2018Q4 imgn Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
25880000
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2761000
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
317000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
317000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
74616000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70660000
CY2018Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
4675000
CY2019Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
145614000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
80485000
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23334000
CY2019Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.045
CY2018Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.045
CY2019Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
29000
CY2018Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
36000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1183335000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-68174000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10972000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287669000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
295381000
CY2019Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15542000
CY2019Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
2071000
CY2018Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
2064000
CY2019Q2 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
1175000
CY2018Q4 imgn Deferred Financing Costs Liability Sale Of Future Royalties Noncurrent
DeferredFinancingCostsLiabilitySaleOfFutureRoyaltiesNoncurrent
1536000
CY2019Q2 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
108265000
CY2018Q4 imgn Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
122345000
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1943000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4180000
CY2019Q2 us-gaap Liabilities
Liabilities
355843000
CY2018Q4 us-gaap Liabilities
Liabilities
284409000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149885000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
149400000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
1498000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1494000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1200860000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1192813000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1270532000
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9287000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
24126000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29102000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28559000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38701000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
67452000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83532000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8700000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8652000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19478000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18647000
CY2019Q2 us-gaap Restructuring Charges
RestructuringCharges
19342000
CY2018Q2 us-gaap Restructuring Charges
RestructuringCharges
686000
us-gaap Restructuring Charges
RestructuringCharges
19901000
us-gaap Restructuring Charges
RestructuringCharges
2417000
us-gaap Operating Expenses
OperatingExpenses
106831000
us-gaap Operating Expenses
OperatingExpenses
104596000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
56601000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
48039000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
147972000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
132512000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43446000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
148129000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
134384000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-41059000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38752000
us-gaap Operating Income Loss
OperatingIncomeLoss
-82705000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75494000
CY2019Q2 us-gaap Investment Income Net
InvestmentIncomeNet
1287000
CY2018Q2 us-gaap Investment Income Net
InvestmentIncomeNet
814000
us-gaap Investment Income Net
InvestmentIncomeNet
2709000
us-gaap Investment Income Net
InvestmentIncomeNet
1476000
CY2019Q2 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
3818000
CY2018Q2 imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
2611000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
7250000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
5657000
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
23000
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
23000
us-gaap Interest Expense Debt
InterestExpenseDebt
47000
us-gaap Interest Expense Debt
InterestExpenseDebt
47000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
167000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1052000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-515000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-43446000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-41624000
us-gaap Net Income Loss
NetIncomeLoss
-87197000
us-gaap Net Income Loss
NetIncomeLoss
-80237000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41624000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87197000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-80237000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-17895000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
14090000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-38613000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2259000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3746000
CY2018Q1 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
102000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-36311000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-41624000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
559000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
162540000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3971000
CY2018Q2 imgn Stock Issued During Period Value Directors Deferred Share Conversion Of Units
StockIssuedDuringPeriodValueDirectorsDeferredShareConversionOfUnits
1000
CY2018Q2 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
54000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
89190000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-46807000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-28000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4308000
CY2018Q3 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
102000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
46889000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-41799000
CY2018Q4 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
1359000
CY2018Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4420000
CY2018Q4 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
103000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10972000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-43751000
CY2019Q1 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
68000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5007000
CY2019Q1 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
100000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-27604000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-43446000
CY2019Q2 imgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
670000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2106000
CY2019Q2 imgn Adjustments To Additional Paid In Capital Directors Deferred Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalDirectorsDeferredShareBasedCompensation
100000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-68174000
us-gaap Profit Loss
ProfitLoss
-87197000
us-gaap Profit Loss
ProfitLoss
-80237000
imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
18900000
imgn Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
14432000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
7250000
imgn Non Cash Interest Expense From Sale Of Future Royalties
NonCashInterestExpenseFromSaleOfFutureRoyalties
5657000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2438000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5056000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2404000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
30000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
559000
us-gaap Share Based Compensation
ShareBasedCompensation
7313000
us-gaap Share Based Compensation
ShareBasedCompensation
7872000
imgn Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
59000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1701000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2630000
imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
1857000
imgn Increase Decrease In Customer Asset
IncreaseDecreaseInCustomerAsset
-2058000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
852000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-500000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2187000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6926000
imgn Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
664000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1859000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
640000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3199000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3871000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
9238000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
162540000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
738000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
165359000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-22427000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239800000
CY2019Q2 imgn Workforce Reduction Number Of Positions
WorkforceReductionNumberOfPositions
220
imgn Current Capital Resources To Meet Operational Expenses And Capital Expenditures Expected Period
CurrentCapitalResourcesToMeetOperationalExpensesAndCapitalExpendituresExpectedPeriod
P12M
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2949000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-5346000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1896000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
65129000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-8196000
imgn Operating Lease Liability Amortization
OperatingLeaseLiabilityAmortization
-1179000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20810000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85281000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2355000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2127000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2355000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2127000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
738000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2819000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
367000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
77951000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262252000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
267107000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239825000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
345058000
us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">A.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><b style="font-weight:bold;">Nature of Business and Plan of Operations</b></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">ImmunoGen, Inc. (the Company) was incorporated in Massachusetts in 1981 and is focused on the development of antibody-drug conjugates, or ADC, therapeutics. The Company has generally incurred operating losses and negative cash flows from operations since inception, incurred a net loss of $87.2 million during the six months ended June 30, 2019, and has an accumulated deficit of approximately $1.3 billion as of June 30, 2019. The Company has primarily funded these losses through payments received from its collaborations and equity and convertible debt financings. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. </p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">At June 30, 2019, the Company had $239.8 million of cash and cash equivalents on hand. On June 26, 2019, the Board of Directors approved a plan to restructure the business to focus resources on continued development of mirvetuximab soravtansine and a select portfolio of three earlier-stage product candidates, resulting in a reduction of workforce by approximately 220 positions. The Company anticipates that its current capital resources and expense reductions resulting from these operational changes will enable it to meet its operational expenses and capital expenditures for more than twelve months after the date these financial statements are issued. The Company may raise additional funds through equity or debt financings or generate revenues from collaborators through a combination of upfront license payments, milestone payments, royalty payments, and research funding. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborators on terms acceptable to the Company or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations, and financial condition and require the Company to defer or limit some or all of its research, development, and/or clinical projects.</p><p style="font-family:'Times New Roman';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, the development by its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, manufacturing and marketing limitations, complexities associated with managing collaboration arrangements, third-party reimbursements, and compliance with governmental regulations.</p><p style="font-family:'Times New Roman';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
us-gaap Profit Loss
ProfitLoss
-87200000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1300000000
CY2019Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
145900000
us-gaap Lease Practical Expedients Package
LeasePracticalExpedientsPackage
true
imgn Unamortized Lease Incentive And Straight Line Lease Liability Balances
UnamortizedLeaseIncentiveAndStraightLineLeaseLiabilityBalances
9700000
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.11
imgn Aggregate Adjustment To Right Of Use Asset
AggregateAdjustmentToRightOfUseAsset
1000000
CY2019Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.24
CY2019Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.76
CY2018Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
500000
us-gaap Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination
0
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
500000
CY2019Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
0
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
80802000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
65287000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
158000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
145931000
CY2017Q4 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
0
us-gaap Contract With Customer Asset Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerAssetIncreaseDecreaseForContractAcquiredInBusinessCombination
0
us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
5000000
CY2018Q2 imgn Contract Asset Impact Of Netting
ContractAssetImpactOfNetting
5000000
CY2018Q2 us-gaap Contract With Customer Asset Gross Current
ContractWithCustomerAssetGrossCurrent
0
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
89967000
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
13196000
CY2018Q2 imgn Contract Liabilities Impact Of Netting
ContractLiabilitiesImpactOfNetting
5000000
CY2018Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
81771000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
79000
CY2018Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1321000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
158000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
13196000
CY2019Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5000000
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
5000000
imgn Cash And Cash Equivalents Number Of Financial Institutions
CashAndCashEquivalentsNumberOfFinancialInstitutions
3
CY2019Q2 us-gaap Marketable Securities
MarketableSecurities
0
CY2018Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
239800000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262300000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
715000
imgn Number Of Trades Impacting Fair Value Of Financial Instruments
NumberOfTradesImpactingFairValueOfFinancialInstruments
0
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2019Q2 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
20223000
CY2018Q2 imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
17776000
imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
20223000
imgn Share Based Compensation Arrangement By Share Based Payment Award Awards Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
17776000
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
432000
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3451000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1005000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3484000
CY2019Q2 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2018Q2 us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
us-gaap Debt Instrument Convertible Number Of Equity Instruments
DebtInstrumentConvertibleNumberOfEquityInstruments
501000
CY2019Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2018Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
501000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2800000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
imgn Number Of Real Estate Leases
NumberOfRealEstateLeases
2
us-gaap Operating Lease Expense
OperatingLeaseExpense
2300000
us-gaap Interest Expense Debt
InterestExpenseDebt
47000
us-gaap Interest Expense Debt
InterestExpenseDebt
47000
imgn Number Of Real Estate Leases
NumberOfRealEstateLeases
2
us-gaap Operating Lease Expense
OperatingLeaseExpense
2800000
us-gaap Operating Lease Payments
OperatingLeasePayments
2600000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
16400000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26100000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2019Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1400000
CY2018Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
595000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
159000
CY2018 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
93000
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2698000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5485000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5324000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5389000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5510000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12336000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
36742000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10647000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
26095000
us-gaap Variable Lease Cost
VariableLeaseCost
3000000.0
CY2019Q2 imgn Collaborative Arrangement Amount Payable Maximum
CollaborativeArrangementAmountPayableMaximum
80000000.0

Files In Submission

Name View Source Status
0001558370-19-007500-index-headers.html Edgar Link pending
0001558370-19-007500-index.html Edgar Link pending
0001558370-19-007500.txt Edgar Link pending
0001558370-19-007500-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imgn-20190630.xsd Edgar Link pending
imgn-20190630ex1015e08d4.htm Edgar Link pending
imgn-20190630ex311db3ebf.htm Edgar Link pending
imgn-20190630x10q.htm Edgar Link pending
imgn-20190630x10q_htm.xml Edgar Link completed
imgn-20190630xex32.htm Edgar Link pending
imgn-20190630_cal.xml Edgar Link unprocessable
imgn-20190630_def.xml Edgar Link unprocessable
imgn-20190630_lab.xml Edgar Link unprocessable
imgn-20190630_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending